Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein

    Authors

    A. Kotha; M. Sekharam; L. Cilenti; K. Siddiquee; A. Khaled; A. S. Zervos; B. Carter; J. Turkson;R. Jove

    Comments

    Authors: contact us about adding a copy of your work at STARS@ucf.edu

    Abbreviated Journal Title

    Mol. Cancer Ther.

    Keywords

    PROSTATE-CANCER CELLS; CHEMOPREVENTIVE AGENT RESVERATROL; BREAST-CARCINOMA CELLS; DNA-BINDING ACTIVITY; NF-KAPPA-B; CONSTITUTIVE; ACTIVATION; MOLECULAR TARGETS; LNCAP CELLS; ANTIESTROGENIC PROPERTIES; ENDOTHELIAL-CELLS; Oncology

    Abstract

    Resveratrol is a naturally occurring phytoalexin with antioxidant and antiinflammatory properties. Recent studies suggest that resveratrol possesses anticancer effects, although its mechanism of action is not well understood. We now show that resveratrol inhibits Src tyrosine kinase activity and thereby blocks constitutive signal transducer and activator of transcription 3 (Stat3) protein activation in malignant cells. Analyses of resveratrol-treated malignant cells harboring constitutively-active Stat3 reveal irreversible cell cycle arrest of v-Src-transformed mouse fibroblasts (NIH3T3/v-Src), human breast (MDA-MB-231), pancreatic (Panc-1), and prostate carcinoma (DU145) cell lines at the GO-G, phase or at the S phase of human breast cancer (MDA-MB-468) and pancreatic cancer (Colo-357) cells, and loss of viability due to apoptosis. By contrast, cells treated with resveratrol, but lacking aberrant Stat3 activity, show reversible growth arrest and minimal loss of viability. Moreover, in malignant cells harboring constitutively-active Stat3, including human prostate cancer DU145 cells and v-Src-transformed mouse fibroblasts (NIH3T3/v-Src), resveratrol treatment represses Stat3-regulated cyclin D1 as well as Bcl-x(L) and Mcl-1 genes, suggesting that the antitumor cell activity of resveratrol is in part due to the blockade of Stat3-mediated dysregulation of growth and survival pathways. Our study is among the first to identify Src-Stat3 signaling as a target of resveratrol, further defining the mechanism of antitumor cell activity of resveratrol and raising its potential application in tumors with an activated Stat3 profile.

    Journal Title

    Molecular Cancer Therapeutics

    Volume

    5

    Issue/Number

    3

    Publication Date

    1-1-2006

    Document Type

    Article

    Language

    English

    First Page

    621

    Last Page

    629

    WOS Identifier

    WOS:000236444500017

    ISSN

    1535-7163

    Share

    COinS